Amphastar Pharmaceuticals, Inc.

NasdaqGS:AMPH 주식 보고서

시가총액: US$2.1b

Amphastar Pharmaceuticals 관리

관리 기준 확인 3/4

Amphastar Pharmaceuticals CEO는 Jack Zhang, Jan1996 에 임명되었습니다 의 임기는 28.83 년입니다. 총 연간 보상은 $ 7.72M, 11.6% 로 구성됩니다. 11.6% 급여 및 88.4% 보너스(회사 주식 및 옵션 포함). 는 $ 101.98M 가치에 해당하는 회사 주식의 4.81% 직접 소유합니다. 101.98M. 경영진과 이사회의 평균 재임 기간은 각각 11 년과 5.4 년입니다.

주요 정보

Jack Zhang

최고 경영자

US$7.7m

총 보상

CEO 급여 비율11.6%
CEO 임기28.8yrs
CEO 소유권4.8%
경영진 평균 재임 기간11yrs
이사회 평균 재임 기간5.4yrs

최근 관리 업데이트

Recent updates

Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)

Oct 25

Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Sep 15
Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines

Sep 12

Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?

Aug 27
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 05
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming

Jul 01

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

May 30
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

Amphastar Pharmaceuticals: Buy When Fear Is Overblown

May 30

Reassessing Amphastar Pharmaceuticals

May 15

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Mar 04

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Jan 04
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Dec 20
Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Dec 03
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

Sep 18
Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Sep 03
An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Aug 17
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Jun 02
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

May 11
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Mar 02
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Feb 07
Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Jan 24
Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Nov 02
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Amphastar: A Pharmaceutical Growth Stock

Oct 06

Amphastar wins FDA approval for Epinephrine pre-filled syringes

Aug 16

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

Aug 08

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 24
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar generic vasopressin for increasing blood pressure gets FDA approval

Jul 19

CEO 보상 분석

Jack Zhang 의 보수는 Amphastar Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

US$158m

Jun 30 2024n/an/a

US$167m

Mar 31 2024n/an/a

US$155m

Dec 31 2023US$8mUS$898k

US$138m

Sep 30 2023n/an/a

US$135m

Jun 30 2023n/an/a

US$102m

Mar 31 2023n/an/a

US$93m

Dec 31 2022US$7mUS$1m

US$91m

Sep 30 2022n/an/a

US$77m

Jun 30 2022n/an/a

US$91m

Mar 31 2022n/an/a

US$81m

Dec 31 2021US$7mUS$898k

US$62m

Sep 30 2021n/an/a

US$36m

Jun 30 2021n/an/a

US$10m

Mar 31 2021n/an/a

US$2m

Dec 31 2020US$6mUS$898k

US$1m

Sep 30 2020n/an/a

US$7m

Jun 30 2020n/an/a

US$4m

Mar 31 2020n/an/a

US$52m

Dec 31 2019US$6mUS$898k

US$49m

Sep 30 2019n/an/a

US$52m

Jun 30 2019n/an/a

US$53m

Mar 31 2019n/an/a

US$2m

Dec 31 2018US$6mUS$1m

-US$6m

Sep 30 2018n/an/a

-US$7m

Jun 30 2018n/an/a

-US$9m

Mar 31 2018n/an/a

-US$4m

Dec 31 2017US$6mUS$880k

US$4m

보상 대 시장: Jack 의 총 보상 ($USD 7.72M )은 US 시장( $USD 5.37M ).

보상과 수익: Jack 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Jack Zhang (77 yo)

28.8yrs

테뉴어

US$7,722,768

보상

Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...


리더십 팀

이름위치테뉴어보상소유권
Ziping Luo
Chairman of the Board28.8yrsUS$3.77m2.12%
$ 45.0m
Yongfeng Zhang
Co-founder28.8yrsUS$7.72m4.81%
$ 102.0m
William Peters
CFO, Executive VP of Finance10.6yrsUS$2.89m0.076%
$ 1.6m
Jacob Liawatidewi
Executive VP of Sales11.4yrsUS$1.78m0.097%
$ 2.0m
Rong Zhou
Senior EVP of Production & EVP of Scientific Affairs9.4yrsUS$2.03m0.39%
$ 8.2m
Dan Dischner
Senior Vice President of Human Resources & Corporate Communication2.3yrs데이터 없음데이터 없음
Tony Marrs
Executive VP of Regulatory Affairs & Clinical Operationsno data데이터 없음데이터 없음

11.0yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 관리: AMPH 의 관리팀은 노련하고 경험 (평균 재직 기간 11 년)입니다.


이사회 구성원

이름위치테뉴어보상소유권
Ziping Luo
Chairman of the Board28.8yrsUS$3.77m2.12%
$ 45.0m
Yongfeng Zhang
Co-founder28.8yrsUS$7.72m4.81%
$ 102.0m
William Peters
CFO, Executive VP of Finance2.3yrsUS$2.89m0.076%
$ 1.6m
Jacob Liawatidewi
Executive VP of Sales2.3yrsUS$1.78m0.097%
$ 2.0m
Richard Prins
Lead Independent Director22.8yrsUS$362.00k0.057%
$ 1.2m
Gayle Deflin
Independent Director3.4yrsUS$330.00k0%
$ 0
Chen Yang
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Paul White
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Gordon Treweek
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Herschel Rabitz
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Richard Porter
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Diane Gerst
Independent Director5.4yrsUS$314.70k0.027%
$ 566.2k

5.4yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: AMPH 의 이사회경험(평균 재직 기간 5.4 년)으로 간주됩니다.